H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on VYGR stock, giving a Buy rating on August 14.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight the potential of Voyager Therapeutics’ innovative platform. The company’s ALPL-based NeuroShuttle demonstrates a promising differentiation from existing transferrin receptor shuttles, showing sustained brain exposure and improved central nervous system durability with minimal peripheral clearance impact. This advancement is seen as enhancing the platform and catalyzing potential partnerships.
Trucchio also points out the strategic interest in the NeuroShuttle, as evidenced by recent high-value transactions in shuttle technology. The ongoing optimization efforts in both rodents and non-human primates, along with the company’s plans to expand their blood-brain barrier transport receptors, further support the positive outlook. The valuation of Voyager is based on a detailed financial model that anticipates significant revenue growth from collaborations and future clinical trials, despite acknowledging various risks associated with clinical development and market dynamics.
In another report released on August 14, Canaccord Genuity also maintained a Buy rating on the stock with a $12.00 price target.